Mga Batayang Estadistika
| LEI | 549300QVPFFJC8SZXG25 |
| CIK | 1595585 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Tricida Inc
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| June 13, 2023 |
As filed with the Securities and Exchange Commission on June 13, 2023 As filed with the Securities and Exchange Commission on June 13, 2023 Registration No. |
|
| June 13, 2023 |
ex991noticeofeffectiveda 30453961.1 IN THE UNITED STATES BANKRUPTCY COURT FOR THE DISTRICT OF DELAWARE In re: TRICIDA, INC.,1 Debtor. Chapter 11 Case No. 23-10024 (JTD) Ref. Docket No. 515 NOTICE OF (I) CONFIRMATION AND EFFECTIVE DATE OF THE FIFTH AMENDED CHAPTER 11 PLAN OF LIQUIDATION FOR TRICIDA, INC. (II) FILING REQUESTS FOR NOTICE OF PLEADINGS FOLLOWING THE EFFECTIVE DATE; AND (III) DEADLINE U |
|
| June 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number 001-38558 TRICIDA, INC. (Exact name of registrant as specified in its charte |
|
| June 13, 2023 |
As filed with the Securities and Exchange Commission on June 13, 2023 As filed with the Securities and Exchange Commission on June 13, 2023 Registration No. |
|
| June 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 12, 2023 TRICIDA, INC. (Exact name of Registrant as specified in its charter) Delaware 001-38558 46-3372526 (State or other jurisdiction of incorporation) (Commission File Number |
|
| June 13, 2023 |
As filed with the Securities and Exchange Commission on June 13, 2023 As filed with the Securities and Exchange Commission on June 13, 2023 Registration No. |
|
| May 25, 2023 |
exhibit991monthlyoperati UST Form 11-MOR (12/01/2021) 1 UNITED STATES BANKRUPTCY COURT DISTRICT OFFOR THE DELAWARE In Re. |
|
| May 25, 2023 |
exhibit21confirmationord 30395810.1 IN THE UNITED STATES BANKRUPTCY COURT FOR THE DISTRICT OF DELAWARE In re: TRICIDA, INC.,1 Debtor. Chapter 11 Case No. 23-10024 (JTD) Re: Docket Nos. 509 & 510 FINDINGS OF FACT, CONCLUSIONS OF LAW, AND ORDER CONFIRMING THE FIFTH AMENDED CHAPTER 11 PLAN OF LIQUIDATION FOR TRICIDA, INC. Tricida, Inc., as debtor and debtor in possession in the above-captioned chapte |
|
| May 25, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 22, 2023 TRICIDA, INC. (Exact name of Registrant as specified in its charter) Delaware 001-38558 46-3372526 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| April 26, 2023 |
exhibit991monthlyoperati UST Form 11-MOR (12/01/2021) 1 UNITED STATES BANKRUPTCY COURT DISTRICT OFFOR THE DELAWARE In Re. |
|
| April 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 21, 2023 TRICIDA, INC. (Exact name of Registrant as specified in its charter) Delaware 001-38558 46-3372526 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| March 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 21, 2023 TRICIDA, INC. (Exact name of Registrant as specified in its charter) Delaware 001-38558 46-3372526 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| March 24, 2023 |
EX-99.1 2 exhibit991monthlyoperati.htm EX-99.1 UST Form 11-MOR (12/01/2021) 1 UNITED STATES BANKRUPTCY COURT DISTRICT OFFOR THE DELAWARE In Re. Tricida, Inc. Debtor(s) § § § § Case No. 23-10024 Jointly Administered Monthly Operating Report Chapter 11 Reporting Period Ended: 02/28/2023 Petition Date: 01/11/2023 Months Pending: 2 Industry Classification: 3 2 5 4 Reporting Method: Accrual Basis Cash |
|
| March 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 15, 2023 TRICIDA, INC. (Exact name of Registrant as specified in its charter) Delaware 001-38558 46-3372526 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| March 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 9, 2023 TRICIDA, INC. (Exact name of Registrant as specified in its charter) Delaware 001-38558 46-3372526 (State or other jurisdiction of incorporation) (Commission File Number |
|
| February 24, 2023 |
exhibit101-aparenibusfu EXECUTION VERSION ASSET PURCHASE AGREEMENT BY AND BETWEEN TRICIDA, INC. |
|
| February 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 21, 2023 TRICIDA, INC. (Exact name of Registrant as specified in its charter) Delaware 001-38558 46-3372526 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| February 24, 2023 |
exhibit102-apaliquiditys ASSET PURCHASE AGREEMENT This ASSET PURCHASE AGREEMENT (“Agreement”) is made as of the Effective Date by and between Liquidity Services Operations LLC, a Delaware limited liability company with a place of business at 6931 Arlington Road, Suite 200, Bethesda, MD 20814 (“Buyer”), and Tricida, Inc. |
|
| February 23, 2023 |
a23100242302210000000000 UST Form 11-MOR (12/01/2021) 1 UNITED STATES BANKRUPTCY COURT DISTRICT OFFOR THE DELAWARE In Re. |
|
| February 23, 2023 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 21, 2023 TRICIDA, INC. (Exact name of Registrant as specified in its charter) Delaware 001-38558 46-3372526 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| February 17, 2023 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 16, 2023 TRICIDA, INC. (Exact name of Registrant as specified in its charter) Delaware 001-38558 46-3372526 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| February 14, 2023 |
TCDA / Tricida Inc / Deep Track Capital, LP Passive Investment SC 13G/A 1 deeptrack-tcda123122a1.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* TRICIDA, INC. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 89610F101 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appr |
|
| February 14, 2023 |
TCDA / Tricida Inc / CITADEL ADVISORS LLC - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G* (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2 (Amendment No. 1)* TRICIDA, INC. (Name of Issuer) Common Stock, par value $0.001 per share (the “Shares”) (Title of Class of Securities) 89610F101 (CUSIP Numb |
|
| February 14, 2023 |
SC 13G/A 1 pt7213gaa.htm SCHEDULE 13G/A, AMENDMENT #2 240.13d-102 Schedule 13G - Information to be included in statements filed pursuant to 240.13d-1(b), (c), and (d) and amendments thereto filed pursuant to 240.13d-2. Securities and Exchange Commission, Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* (Name of Issuer) Tricida, Inc. (Title of Class o |
|
| February 14, 2023 |
TCDA / Tricida Inc / Frazier Life Sciences Public Fund, L.P. - SC 13G/A Passive Investment SC 13G/A SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. |
|
| February 14, 2023 |
EX-99.1 2 pt7213gab.htm JOINT FILING AGREEMENT Exhibit 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, and that all subsequent amendments to this statement on Schedule 13G may be filed on behalf |
|
| January 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 23, 2023 TRICIDA, INC. (Exact name of Registrant as specified in its charter) Delaware 001-38558 46-3372526 (State or other jurisdiction of incorporation) (Commission File Num |
|
| January 17, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 13, 2023 TRICIDA, INC. (Exact name of Registrant as specified in its charter) Delaware 001-38558 46-3372526 (State or other jurisdiction of incorporation) (Commission File Num |
|
| January 12, 2023 |
Amended and Restated Bylaws of Tricida, Inc., dated January 10, 2023. ex31-tcdaxamendedandrest Exhibit 3.1 AMENDED AND RESTATED BYLAWS OF TRICIDA, INC. (hereinafter called the “Corporation”) ARTICLE I MEETINGS OF STOCKHOLDERS Section 1.1. Place of Meetings. Meetings of the stockholders of the Corporation for the election of directors or for any other purpose shall be held at such time and place, either within or without the State of Delaware, as shall be designated |
|
| January 12, 2023 |
Independent Director Agreement between the Company and Thomas G. FitzGerald. exhibit102fitzgeraldind 1 INDEPENDENT DIRECTOR AGREEMENT THIS INDEPENDENT DIRECTOR AGREEMENT (the “Agreement”) is made as of December 23, 2022, by and between Tricida, Inc. |
|
| January 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 9, 2023 TRICIDA, INC. (Exact name of Registrant as specified in its charter) Delaware 001-38558 46-3372526 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| January 12, 2023 |
exhibit101tricida-restr THIS RESTRUCTURING SUPPORT AGREEMENT IS NOT AN OFFER OR ACCEPTANCE WITH RESPECT TO ANY SECURITIES OR A SOLICITATION OF ACCEPTANCES OF A CHAPTER 11 PLAN WITHIN THE MEANING OF SECTION 1125 OF THE BANKRUPTCY CODE. |
|
| January 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 28, 2022 TRICIDA, INC. (Exact name of Registrant as specified in its charter) Delaware 001-38558 46-3372526 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| December 22, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 19, 2022 TRICIDA, INC. (Exact name of Registrant as specified in its charter) Delaware 001-38558 46-3372526 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| December 16, 2022 |
TCDA / Tricida Inc / Sibling Capital Ventures Llc - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 6) Tricida, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 89610F101 (CUSIP Number) Sibling Capital Ventures LLC c/o Brian Isern 2033 6th Ave, Suite 330 Seattle, WA 98121 Tel: (504) 715-8335 (Name, Address and T |
|
| December 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 7, 2022 TRICIDA, INC. (Exact name of Registrant as specified in its charter) Delaware 001-38558 46-3372526 (State or other jurisdiction of incorporation) (Commission File Num |
|
| December 7, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 6, 2022 TRICIDA, INC. (Exact name of Registrant as specified in its charter) Delaware 001-38558 46-3372526 (State or other jurisdiction of incorporation) (Commission File Num |
|
| November 25, 2022 |
Exhibit 1 JOINT FILING AGREEMENT The undersigned hereby agree that the Statement on Schedule 13D, dated November 22, 2022, with respect to the common stock of Tricida, Inc. |
|
| November 25, 2022 |
TCDA / Tricida Inc / ORBIMED ADVISORS LLC - AMENDMENT NO. 3 Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 3)* Tricida, Inc. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 89610F101 (CUSIP Number) OrbiMed Advisors LLC OrbiMed Capital GP V LLC 601 Lexington Avenue, 54th Floor New York, NY 10022 Telephone: (212) 739-6400 (Name, Address and Telephone N |
|
| November 17, 2022 |
tricida-companypresentat Summary of the Veverimer Opportunity Post-VALOR-CKD Data November 2022 Exhibit 99. |
|
| November 17, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 15, 2022 TRICIDA, INC. (Exact name of Registrant as specified in its charter) Delaware 001-38558 46-3372526 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| November 14, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2022 TRICIDA, INC. (Exact name of Registrant as specified in its charter) Delaware 001-38558 46-3372526 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| November 14, 2022 |
AMENDMENT NO. 4 TO MANUFACTURING AND COMMERCIAL SUPPLY AGREEMENT This Amendment No. 4 to Manufacturing and Commercial Supply Agreement (?Amendment No. 4?) is dated as of September 15, 2022 (the ?Amendment No. 4 Effective Date?) and is entered into between Patheon Austria GmbH & Co KG, with its principal offices located at St. Peter Strasse 25, A-4020 Linz, Austria (?Patheon?), and Tricida, Inc., a |
|
| November 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38558 TRICIDA, INC. (E |
|
| November 14, 2022 |
AMENDMENT NO. 3 TO MANUFACTURING AND COMMERCIAL SUPPLY AGREEMENT This Amendment No. 3 to Manufacturing and Commercial Supply Agreement (?Amendment No. 3?) is dated as of July 1, 2022 (the ?Amendment No. 3 Effective Date?) and is entered into between Patheon Austria GmbH & Co KG, with its principal offices located at St. Peter Strasse 25, A-4020 Linz, Austria (?Patheon?), and Tricida, Inc., a Delaw |
|
| November 14, 2022 |
Tricida Announces Third Quarter 2022 Financial Results Exhibit 99.1 FOR IMMEDIATE RELEASE Tricida Announces Third Quarter 2022 Financial Results SOUTH SAN FRANCISCO, Calif., November 14, 2022 ? Tricida, Inc. (Nasdaq: TCDA) announced today financial results for the three and nine months ended September 30, 2022 and provided an update on key initiatives. Business Update ?Tricida announced in October the top-line results from its VALOR-CKD renal outcomes |
|
| November 2, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 2, 2022 TRICIDA, INC. (Exact name of Registrant as specified in its charter) Delaware 001-38558 46-3372526 (State or other jurisdiction of incorporation) (Commission File Num |
|
| November 2, 2022 |
Tricida Provides Strategic Update Exhibit 99.1 FOR IMMEDIATE RELEASE Tricida Provides Strategic Update SOUTH SAN FRANCISCO, Calif., November 2, 2022 (Business Wire) —Tricida, Inc. (NASDAQ: TCDA), announced today that the Board of Directors has authorized Tricida to initiate a review of strategic alternatives to maximize stakeholder value. To facilitate this review, Tricida has engaged Stifel and its wholly owned affiliate, Miller |
|
| October 28, 2022 |
TCDA / Tricida Inc / CITADEL ADVISORS LLC - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G* (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2 (Amendment No. )* Tricida, Inc. (Name of Issuer) Common stock, par value $0.001 per share (the “Shares”) (Title of Class of Securities) 89610F101 (CUSIP Numbe |
|
| October 28, 2022 |
TCDA / Tricida Inc / Venrock Healthcare Capital Partners II, L.P. - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 3)* Tricida, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 89610F101 (CUSIP Number) October 25, 2022 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule pursuant to w |
|
| October 28, 2022 |
EXHIBIT 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that the Statement on Schedule 13G filed herewith (and any amendments thereto), relating to the Shares of Tricida, Inc., a Delaware corporation, is being filed jointly with the Securities and Exchange Commission pursuant to Rule 13d-1(c) under the Securities Exchange Act of 1934, as amended, on behalf of each of the undersigned. This |
|
| October 24, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 24, 2022 TRICIDA, INC. (Exact name of Registrant as specified in its charter) Delaware 001-38558 46-3372526 (State or other jurisdiction of incorporation) (Commission File Num |
|
| October 24, 2022 |
Exhibit 99.1 FOR IMMEDIATE RELEASE Tricida Reports Topline Results from the VALOR-CKD Phase 3 Trial of Veverimer Webcast today at 8:00 am Eastern Time SOUTH SAN FRANCISCO, Calif., October 24, 2022 (Business Wire) —Tricida, Inc. (NASDAQ: TCDA), announced today the top-line results from its VALOR-CKD renal outcomes clinical trial, designed to evaluate veverimer’s ability to slow CKD progression in p |
|
| October 20, 2022 |
Exhibit 10.1 LOAN AND SECURITY AGREEMENT THIS LOAN AND SECURITY AGREEMENT is made and dated as of October 19, 2022 (as amended, modified or supplemented from time to time, this ?Agreement?) and is entered into by and among Tricida, Inc., a Delaware corporation, and each of its Qualified Subsidiaries from time to time party hereto (hereinafter collectively referred to as the ?Borrower?), the severa |
|
| October 20, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 19, 2022 TRICIDA, INC. (Exact name of Registrant as specified in its charter) Delaware 001-38558 46-3372526 (State or other jurisdiction of incorporation) (Commission File Num |
|
| October 19, 2022 |
TCDA / Tricida Inc / Sibling Capital Ventures Llc - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 5) Tricida, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 89610F101 (CUSIP Number) Sibling Capital Ventures LLC c/o Brian Isern 2033 6th Ave, Suite 330 Seattle, WA 98121 Tel: (504) 715-8335 (Name, Address and T |
|
| September 29, 2022 |
TCDA / Tricida Inc / Venrock Healthcare Capital Partners II, L.P. - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 2)* Tricida, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 89610F101 (CUSIP Number) September 26, 2022 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule pursuant to |
|
| September 23, 2022 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 19, 2022 TRICIDA, INC. (Exact name of Registrant as specified in its charter) Delaware 001-38558 46-3372526 (State or other jurisdiction of incorporation) (Commission File N |
|
| August 8, 2022 |
Tricida Announces Second Quarter 2022 Financial Results Webcast Today at 4:30 pm Eastern Time Exhibit 99.1 FOR IMMEDIATE RELEASE Tricida Announces Second Quarter 2022 Financial Results Webcast Today at 4:30 pm Eastern Time SOUTH SAN FRANCISCO, Calif., August 8, 2022 ? Tricida, Inc. (Nasdaq: TCDA) announced today financial results for the three and six months ended June 30, 2022 and provided an update on key initiatives. Business Update ?Tricida announced in May 2022 that it stopped its VAL |
|
| August 8, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2022 TRICIDA, INC. (Exact name of Registrant as specified in its charter) Delaware 001-38558 46-3372526 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| August 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38558 TRICIDA, INC. (Exact |
|
| August 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 30, 2022 TRICIDA, INC. (Exact name of Registrant as specified in its charter) Delaware 001-38558 46-3372526 (State or other jurisdiction of incorporation) (Commission File Number |
|
| June 16, 2022 |
Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 15, 2022 TRICIDA, INC. (Exact name of Registrant as specified in its charter) Delaware 001-38558 46-3372526 (State or other jurisdiction of incorporation) (Commission File Number |
|
| June 7, 2022 |
TCDA / Tricida Inc / Venrock Healthcare Capital Partners II, L.P. - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1)* Tricida, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 89610F101 (CUSIP Number) June 1, 2022 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule pursuant to which |
|
| May 19, 2022 |
Exhibit 99.1 FOR IMMEDIATE RELEASE Tricida Announces Administrative Stop of the VALOR-CKD Trial Expects to Announce Top-Line Results Early in the Fourth Quarter of 2022 SOUTH SAN FRANCISCO, Calif., May 19, 2022 ? Tricida, Inc. (Nasdaq: TCDA) announced today that as anticipated it is stopping its VALOR-CKD renal outcomes trial early for administrative reasons pursuant to the existing study protocol |
|
| May 19, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 19, 2022 TRICIDA, INC. (Exact name of Registrant as specified in its charter) Delaware 001-38558 46-3372526 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| May 17, 2022 |
May 17, 2022 Via EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549-3720 Attention: Jessica Ansart Re: Acceleration Request for Tricida, Inc. Registration Statement on Form S-3 (File No. 333-264835) Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended, Tricida, Inc. (the “Company”), hereby reque |
|
| May 16, 2022 |
TCDA / Tricida Inc / Frazier Life Sciences Public Fund, L.P. - SC 13G Passive Investment SC 13G SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. |
|
| May 16, 2022 |
EXHIBIT A AGREEMENT Pursuant to Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, the undersigned hereby agree that only one statement containing the information required by Schedule 13G need be filed with respect to the ownership by each of the undersigned of Common Stock of Tricida, Inc. |
|
| May 10, 2022 |
Tricida Announces First Quarter 2022 Financial Results Webcast Today at 4:30 pm Eastern Time Exhibit 99.1 FOR IMMEDIATE RELEASE Tricida Announces First Quarter 2022 Financial Results Webcast Today at 4:30 pm Eastern Time SOUTH SAN FRANCISCO, Calif., May 10, 2022 ? Tricida, Inc. (Nasdaq: TCDA) announced today financial results for the three months ended March 31, 2022 and provided an update on key initiatives. Business Update ?Tricida continued to execute on the conduct of the VALOR-CKD re |
|
| May 10, 2022 |
Exhibit 107 Calculation of Filing Fee Tables FORM S-3 (Form Type) Tricida, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price(1) Fee Rate Amount of Registration Fee(2) Car |
|
| May 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38558 TRICIDA, INC. (Exact |
|
| May 10, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 10, 2022 TRICIDA, INC. (Exact name of Registrant as specified in its charter) Delaware 001-38558 46-3372526 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| May 10, 2022 |
As filed with the Securities and Exchange Commission on May 10, 2022 As filed with the Securities and Exchange Commission on May 10, 2022 Registration No. |
|
| April 25, 2022 |
DEFA14A 1 ny20002685x2defa14a.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary P |
|
| April 25, 2022 |
DEF 14A 1 ny20002685x1def14a.htm DEF 14A TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box |
|
| March 29, 2022 |
Exhibit 99.1 FOR IMMEDIATE RELEASE Tricida Announces Fourth Quarter and Full Year 2021 Financial Results Webcast Today at 4:30 pm Eastern Time SOUTH SAN FRANCISCO, Calif., March 29, 2022 ? Tricida, Inc. (Nasdaq: TCDA) announced today financial results for the three months and year ended December 31, 2021 and provided an update on key initiatives. Business Update ?Tricida continued to execute on th |
|
| March 29, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 29, 2022 TRICIDA, INC. (Exact name of Registrant as specified in its charter) Delaware 001-38558 46-3372526 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| March 29, 2022 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period From To Commission File Number: 001-38558 TRICIDA, INC. (Exact name of |
|
| March 24, 2022 |
TCDA / Tricida Inc / Sibling Capital Ventures Llc - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 4) Tricida, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 89610F101 (CUSIP Number) Sibling Capital Ventures LLC c/o Brian Isern 2033 6th Ave, Suite 330 Seattle, WA 98121 Tel: (504) 715-8335 (Name, Address and T |
|
| March 2, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 2, 2022 TRICIDA, INC. (Exact name of Registrant as specified in its charter) Delaware 001-38558 46-3372526 (State or other jurisdiction of incorporation) (Commission File Number |
|
| March 2, 2022 |
Exhibit 99.1 FOR IMMEDIATE RELEASE Tricida Provides Update on Timing of Top-Line Data for the VALOR-CKD Trial Based on Conflict in Ukraine SOUTH SAN FRANCISCO, Calif., March 2, 2022 ? Tricida, Inc. (Nasdaq: TCDA), a pharmaceutical company focused on the development and commercialization of its investigational drug candidate, veverimer, a non-absorbed, orally-administered polymer designed to slow c |
|
| February 14, 2022 |
240.13d-102 Schedule 13G - Information to be included in statements filed pursuant to 240.13d-1(b), (c), and (d) and amendments thereto filed pursuant to 240.13d-2. Securities and Exchange Commission, Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.1)* (Name of Issuer) Tricida, Inc. (Title of Class of Securities) Common Stock, Par Value $0.001 Per Share |
|
| February 14, 2022 |
TCDA / Tricida Inc / Venrock Healthcare Capital Partners II, L.P. - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. )* Tricida, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 89610F101 (CUSIP Number) November 17, 2021 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule pursuant to wh |
|
| January 14, 2022 |
As filed with the Securities and Exchange Commission on January 14, 2022 As filed with the Securities and Exchange Commission on January 14, 2022 Registration No. |
|
| January 10, 2022 |
Slowing the Progression of Chronic Kidney Disease Tricida Investor Presentation January 2022 Exhibit 99. |
|
| January 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 7, 2022 TRICIDA, INC. (Exact name of Registrant as specified in its charter) Delaware 001-38558 46-3372526 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| November 23, 2021 |
TCDA / Tricida Inc / Sibling Capital Ventures Llc - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 3) Tricida, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 89610F101 (CUSIP Number) Sibling Capital Ventures LLC c/o Brian Isern 2033 6th Ave, Suite 330 Seattle, WA 98121 Tel: (504) 715-8335 (Name, Address and T |
|
| November 17, 2021 |
TCDA / Tricida Inc / Deep Track Capital, LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| November 15, 2021 |
Form of the Common Stock Purchase Warrant. Exhibit 4.1 COMMON STOCK PURCHASE WARRANT TRICIDA, INC. Warrant Shares: [ ] Issue Date : November , 2021 THIS COMMON STOCK PURCHASE WARRANT (the ?Warrant?) certifies that, for value received, [?] or its assigns (the ?Holder?) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date that is six (6) months after |
|
| November 15, 2021 |
Tricida Raises $42 Million in Registered Direct Equity Financing Filed pursuant to Rule 433 Issuer Free Writing Prospectus Registration Statement No. |
|
| November 15, 2021 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this ?Agreement?) is dated as of November 12, 2021, between Tricida, Inc., a Delaware corporation (the ?Company?), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a ?Purchaser? and collectively the ?Purchasers?). WHEREAS, subject to the terms and conditions set fo |
|
| November 15, 2021 |
Form of the Pre-Funded Purchase Warrant. Exhibit 4.2 PREFUNDED COMMON STOCK PURCHASE WARRANT TRICIDA, INC. Warrant Shares: Initial Exercise Date: November , 2021 THIS PREFUNDED COMMON STOCK PURCHASE WARRANT (the ?Warrant?) certifies that, for value received, or its assigns (the ?Holder?) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date set fo |
|
| November 15, 2021 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 15, 2021 (November 12, 2021) TRICIDA, INC. (Exact name of Registrant as specified in its charter) Delaware 001-38558 46-3372526 (State or other jurisdiction of incorporation) |
|
| November 15, 2021 |
Table of Contents Filed Pursuant to Rule 424(b)5) Registration No. 333-252359 4,666,667 Shares of Common Stock Pre-Funded Warrants to Purchase up to 2,333,333 Shares of Common Stock Common Warrants to Purchase up to 7,000,000 Shares of Common Stock We are offering directly 4,666,667 shares of our common stock at $6.00 per share, pre-funded warrants to purchase up to 2,333,333 shares of common stoc |
|
| November 15, 2021 |
Tricida Raises $42 Million in Registered Direct Equity Financing Exhibit 99.1 Tricida Raises $42 Million in Registered Direct Equity Financing SOUTH SAN FRANCISCO, Calif., November 15, 2021 ? Tricida, Inc. (Nasdaq: TCDA), a pharmaceutical company focused on the development and commercialization of its investigational drug candidate, veverimer, a non-absorbed, orally-administered polymer designed to slow chronic kidney disease (CKD) progression in patients with |
|
| November 8, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38558 TRICIDA, INC. (E |
|
| November 8, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 5, 2021 TRICIDA, INC. (Exact name of Registrant as specified in its charter) Delaware 001-38558 46-3372526 (State or other jurisdiction of incorporation) (Commission File Num |
|
| November 8, 2021 |
Tricida, Inc. Executive Retention Agreement Template Amendment Exhibit 10.2 2020 Retention Agreement Amendment Dear <>, In recognition of the important role you have today and in anticipation of your contributions moving forward, Tricida, Inc. (?Company?) previously offered you retention awards in the form of equity and cash pursuant to the terms of a Retention Agreement, dated September 10, 2020 (the ?2020 Retention Agreement?). The equity and cash awards we |
|
| November 8, 2021 |
Exhibit 10.1 Certain information contained in this document, marked by [***], has been omitted because it is both (i) not material and (ii) the type of information that Tricida, Inc. treats as private or confidential. AMENDMENT NO. 2 TO MANUFACTURING AND COMMERCIAL SUPPLY AGREEMENT This Amendment No. 2 to Manufacturing and Commercial Supply Agreement (?Amendment No. 2?) is dated as of August 26, 2 |
|
| November 8, 2021 |
Tricida Announces Third Quarter 2021 Financial Results Webcast Today at 4:30 pm Eastern Time Exhibit 99.1 FOR IMMEDIATE RELEASE Tricida Announces Third Quarter 2021 Financial Results Webcast Today at 4:30 pm Eastern Time SOUTH SAN FRANCISCO, Calif., November 8, 2021 ? Tricida, Inc. (Nasdaq: TCDA), a pharmaceutical company focused on the development and commercialization of its investigational drug candidate, veverimer, a non-absorbed, orally-administered polymer designed to slow chronic k |
|
| August 31, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 26, 2021 TRICIDA, INC. (Exact name of Registrant as specified in its charter) Delaware 001-38558 46-3372526 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| August 16, 2021 |
SC TO-I/A 1 formscto-iatenderofferstat.htm SC TO-I/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO/A (Amendment No. 1) Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 TRICIDA, INC. (Name of Subject Company (Issuer) and Filing Person (Offeror)) Options to Purchase Common Stock, Par Value $0.001 Per Share (Title o |
|
| August 16, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 12, 2021 TRICIDA, INC. (Exact name of Registrant as specified in its charter) Delaware 001-38558 46-3372526 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| August 9, 2021 |
Tricida Announces Second Quarter 2021 Financial Results Webcast Today at 4:30 pm Eastern Time EX-99.1 2 q22021financialresultsrele.htm EX-99.1 Exhibit 99.1 FOR IMMEDIATE RELEASE Tricida Announces Second Quarter 2021 Financial Results Webcast Today at 4:30 pm Eastern Time SOUTH SAN FRANCISCO, Calif., August 9, 2021 — Tricida, Inc. (Nasdaq: TCDA), a pharmaceutical company focused on the development and commercialization of its investigational drug candidate, veverimer, a non-absorbed, orally |
|
| August 9, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 9, 2021 TRICIDA, INC. (Exact name of Registrant as specified in its charter) Delaware 001-38558 46-3372526 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| August 9, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38558 TRICIDA, INC. (Exact |
|
| July 15, 2021 |
Form of Option Award Notice under 2018 Equity Incentive Plan. Exhibit (a)(1)(K) Tricida, Inc. 2018 Equity Incentive Plan Option Award Notice [Name of Holder] You have been awarded an option to purchase shares of Common Stock of Tricida, Inc., a Delaware corporation (the ?Company?), pursuant to the terms and conditions of the Tricida, Inc. 2018 Equity Incentive Plan (the ?Plan?) and the Stock Option Agreement (together with this Award Notice, the ?Agreement?) |
|
| July 15, 2021 |
Exhibit (a)(1)(C) TRICIDA, INC. 7000 Shoreline Court, Suite 201 SOUTH SAN FRANCISCO, CA 94080 OPTION EXCHANGE ? ELECTION FORM THIS OFFER AND YOUR WITHDRAWAL RIGHTS WILL EXPIRE AT 6:00 P.M., PACIFIC TIME, ON THURSDAY, AUGUST 12, 2021, UNLESS EXTENDED Before completing and signing this Election Form, we encourage you to read the documents that make up this tender offer, including (1) the Offer to Ex |
|
| July 15, 2021 |
Form of Email Confirming Receipt of Notice of Withdrawal of Election Form Exhibit (a)(1)(F) FORM OF EMAIL CONFIRMING RECEIPT OF NOTICE OF WITHDRAWAL OF ELECTION FORM From: TRICIDA, INC. |
|
| July 15, 2021 |
Offer to Exchange Eligible Options for New Options, dated July 16, 2021 Exhibit (a)(1)(A) TRICIDA, INC. 7000 SHORELINE COURT, SUITE 201 SOUTH SAN FRANCISCO, CALIFORNIA 94080 OFFER TO EXCHANGE ELIGIBLE OPTIONS FOR NEW OPTIONS JULY 16, 2021 TRICIDA, INC. SUMMARY TERM SHEET ? OVERVIEW OFFER TO EXCHANGE ELIGIBLE OPTIONS FOR NEW OPTIONS This offer and withdrawal rights will expire at 6:00 p.m., Pacific Time, on August 12, 2021, unless extended By this Offer to Exchange Eli |
|
| July 15, 2021 |
Form of Email to Eligible Holders Confirming Acceptance of Eligible Options Exhibit (a)(1)(H) FORM OF EMAIL TO ELIGIBLE HOLDERS CONFIRMING ACCEPTANCE OF ELIGIBLE OPTIONS From: TRICIDA, INC. |
|
| July 15, 2021 |
Form of Expiration Notice Email Exhibit (a)(1)(J) FORM OF EXPIRATION NOTICE EMAIL From: TRICIDA, INC. Re: Expiration of the Exchange Offer The Exchange Offer described in the Offer to Exchange Eligible Options for New Options, dated July 16, 2021 (the ?Offer Documents?), has expired, and no additional Election Forms or Notices of Withdrawal may be submitted. If you are an Eligible Holder and delivered a properly completed and si |
|
| July 15, 2021 |
Form of Email Confirming Receipt of Election Form Exhibit (a)(1)(E) FORM OF EMAIL CONFIRMING RECEIPT OF ELECTION FORM From: TRICIDA, INC. |
|
| July 15, 2021 |
Notice of Withdrawal of Election Form Exhibit (a)(1)(D) INSTRUCTIONS TO NOTICE OF WITHDRAWAL OF ELECTION FORM If you previously elected to accept the offer by TRICIDA, INC. |
|
| July 15, 2021 |
Form of Announcement Email to Eligible Holders Exhibit (a)(1)(B) FORM OF ANNOUNCEMENT EMAIL TO ELIGIBLE HOLDERS Subject: TRICIDA, INC. |
|
| July 15, 2021 |
Form of Email Notice Regarding Rejection of Options for Exchange Exhibit (a)(1)(I) FORM OF EMAIL NOTICE REGARDING REJECTION OF OPTIONS FOR EXCHANGE From: TRICIDA, INC. |
|
| July 15, 2021 |
Form of Reminder Email to Eligible Holders Regarding the Expiration of the Exchange Offer Exhibit (a)(1)(G) FORM OF REMINDER EMAIL TO ELIGIBLE HOLDERS REGARDING THE EXPIRATION OF THE EXCHANGE OFFER From: TRICIDA, INC. |
|
| July 15, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO (Rule 13e-4) Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 TRICIDA, INC. (Name of Subject Company (Issuer) and Filing Person (Offeror)) Options to Purchase Common Stock, Par Value $0.001 Per Share (Title of Class of Securities) 89610F101 (CUSIP Number of Class of S |
|
| June 15, 2021 |
Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 10, 2021 TRICIDA, INC. (Exact name of Registrant as specified in its charter) Delaware 001-38558 46-3372526 (State or other jurisdiction of incorporation) (Commission File Number |
|
| May 7, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38558 TRICIDA, INC. (Exact |
|
| May 7, 2021 |
Exhibit 10.1 Certain information contained in this document, marked by [***], has been omitted because it is both (i) not material and (ii) the type of information that Tricida, Inc. treats as private or confidential. AMENDMENT NO. 1 TO MANUFACTURING AND COMMERCIAL SUPPLY AGREEMENT This Amendment No. 1 to Manufacturing and Commercial Supply Agreement (?Amendment No. 1?) is dated as of March 30, 20 |
|
| May 6, 2021 |
Tricida Announces First Quarter 2021 Financial Results Webcast Today at 4:30 pm Eastern Time Exhibit 99.1 FOR IMMEDIATE RELEASE Tricida Announces First Quarter 2021 Financial Results Webcast Today at 4:30 pm Eastern Time SOUTH SAN FRANCISCO, Calif., May 6, 2021 ? Tricida, Inc. (Nasdaq: TCDA), a pharmaceutical company focused on the development and commercialization of its investigational drug candidate, veverimer, a non-absorbed, orally-administered polymer designed to treat metabolic aci |
|
| May 6, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 6, 2021 TRICIDA, INC. (Exact name of Registrant as specified in its charter) Delaware 001-38558 46-3372526 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| April 23, 2021 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant?? ? ? Filed by a Party other than the Registrant??? Check the appropriate box: ?? ? ? Preliminary Proxy Statement ?? ? ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? ? ? Definitive Proxy Statement ?? ? ? Definitive Additional Materials ?? ? ? Soliciting Material under ? 240. |
|
| April 23, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 ? Filed by the Registrant ? Filed by a Party other than the Registrant Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy Statement ? Definitive Additional Materials ? Soliciting Material under ? 240. |
|
| April 12, 2021 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant?? ? ? Filed by a Party other than the Registrant??? Check the appropriate box: ? ? ? Preliminary Proxy Statement ?? ? ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ?? ? ? Definitive Proxy Statement ?? ? ? Definitive Additional Materials ?? ? ? Soliciting Material under ? 240. |
|
| April 1, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 30, 2021 TRICIDA, INC. (Exact name of Registrant as specified in its charter) Delaware 001-38558 46-3372526 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| March 24, 2021 |
Exhibit 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, and that all subsequent amendments to this statement on Schedule 13G may be filed on behalf of each of the undersigned without the necessi |
|
| March 24, 2021 |
240.13d-102 Schedule 13G - Information to be included in statements filed pursuant to 240.13d-1(b), (c), and (d) and amendments thereto filed pursuant to 240.13d-2. Securities and Exchange Commission, Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.)* (Name of Issuer) Tricida, Inc. (Title of Class of Securities) Common Stock, Par Value $0.001 Per Share ( |
|
| March 18, 2021 |
March 18, 2021 Via EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549-3720 Attention: Jeffrey Gabor Re: Acceleration Request for Tricida, Inc. Registration Statement on Form S-3 (File No. 333-252359) Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended, Tricida, Inc. (the ?Company?), hereby requ |
|
| March 18, 2021 |
As filed with the Securities and Exchange Commission on March 17, 2021 Registration No. |
|
| March 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 12, 2021 TRICIDA, INC. (Exact name of Registrant as specified in its charter) Delaware 001-38558 46-3372526 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| March 2, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 26, 2021 TRICIDA, INC. (Exact name of Registrant as specified in its charter) Delaware 001-38558 46-3372526 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| March 2, 2021 |
Treating Metabolic Acidosis and Slowing the Progression of Chronic Kidney Disease Investor Presentation March 2021 Exhibit 99. |
|
| February 26, 2021 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period From To Commission File Number: 001-38558 TRICIDA, INC. (Exact name of |
|
| February 26, 2021 |
Description of the Company's Common Stock, $0.001 par value. Exhibit 4.13 DESCRIPTION OF REGISTRANT?S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The authorized capital stock of Tricida, Inc. consists of 440,000,000 shares, consisting of 400,000,000 shares of common stock, par value $0.001 per share (the ?common stock?) and 40,000,000 shares of preferred stock, par value $0.001 per share (the ?preferred stock?). We ha |
|
| February 26, 2021 |
738350474.4 1 Exhibit 10.17 FOURTH AMENDMENT TO LEASE THIS FOURTH AMENDMENT TO LEASE (this ?Fourth Amendment?) is made as of December 14, 2020 (?Effective Date?), by and between ARE-SAN FRANCISCO NO. 17, LLC, a Delaware limited liability company (?Landlord?), and TRICIDA, INC., a Delaware corporation (?Tenant?). RECITALS A. Landlord and Tenant are now parties to that certain Lease Agreement dated |
|
| February 25, 2021 |
Exhibit 99.2 FOR IMMEDIATE RELEASE Tricida Provides Update on FDA Interactions Tricida Has Received an Appeal Denied Letter from the Office of New Drugs of the FDA in Response to its Formal Dispute Resolution Request SOUTH SAN FRANCISCO, Calif., February 25, 2021 ? Tricida, Inc. (Nasdaq: TCDA), a pharmaceutical company focused on the development and commercialization of its investigational drug ca |
|
| February 25, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 25, 2021 TRICIDA, INC. (Exact name of Registrant as specified in its charter) Delaware 001-38558 46-3372526 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| February 25, 2021 |
Tricida Announces Fourth Quarter and Full Year 2020 Financial Results Exhibit 99.1 FOR IMMEDIATE RELEASE Tricida Announces Fourth Quarter and Full Year 2020 Financial Results SOUTH SAN FRANCISCO, Calif., February 25, 2021 ? Tricida, Inc. (Nasdaq: TCDA), a pharmaceutical company focused on the development and commercialization of its investigational drug candidate, veverimer (TRC101), a non-absorbed, orally-administered polymer designed to treat metabolic acidosis in |
|
| February 22, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 16, 2021 TRICIDA, INC. (Exact name of Registrant as specified in its charter) Delaware 001-38558 46-3372526 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| February 4, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2 )* TRICIDA, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 89610F101 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule |
|
| January 22, 2021 |
Form of Sales Agreement between the Registrant and Cowen and Company, LLC. Exhibit 1.2 TRICIDA, INC. $75,000,000 COMMON STOCK SALES AGREEMENT [], 2021 Cowen and Company, LLC 599 Lexington Avenue New York, NY 10022 Ladies and Gentlemen: Tricida, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Cowen and Company, LLC (“Cowen”), as follows: 1.Issuance and Sale of Shares. The Company agrees that, from time to time during the term o |
|
| January 22, 2021 |
As filed with the Securities and Exchange Commission on January 22, 2021 Registration No. |
|
| January 11, 2021 |
exhibit101hercules6tham Exhibit 10.1 1 SIXTH AMENDMENT TO LOAN AND SECURITY AGREEMENT This SIXTH AMENDMENT TO LOAN AND SECURITY AGREEMENT (this “Amendment”), dated as of January 6, 2021 (the “Sixth Amendment Effective Date”), is entered into by and among Tricida, Inc. (the “Borrower”), the several banks and other financial institutions or entities from time to time party thereto (collectively, “Le |
|
| January 11, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 11, 2021 TRICIDA, INC. (Exact name of Registrant as specified in its charter) Delaware 001-38558 46-3372526 (State or other jurisdiction of incorporation) (Commission File Num |
|
| January 11, 2021 |
exhibit991presentationx Treating Metabolic Acidosis and Slowing the Progression of Chronic Kidney Disease Investor Presentation January 2021 Exhibit 99. |
|
| January 11, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 6, 2021 TRICIDA, INC. (Exact name of Registrant as specified in its charter) Delaware 001-38558 46-3372526 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| January 11, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 11, 2021 TRICIDA, INC. (Exact name of Registrant as specified in its charter) Delaware 001-38558 46-3372526 (State or other jurisdiction of incorporation) (Commission File N |
|
| January 8, 2021 |
(incorporated by reference to Exhibit tricida-inducementplanx2 TRICIDA, INC. 2020 INDUCEMENT PLAN 1. PURPOSE OF PLAN The purpose of this Tricida, Inc. 2020 Inducement Plan (this “Plan”) of Tricida, Inc., a Delaware corporation (the “Company”), is to advance the interests of the Company by providing a material inducement for the best available individuals to join the Company and its Subsidiaries as employees by affording such individua |
|
| January 8, 2021 |
As filed with the Securities and Exchange Commission on January 8, 2021 Registration No. |
|
| January 8, 2021 |
As filed with the Securities and Exchange Commission on January 8, 2021 Registration No. |
|
| December 8, 2020 |
Treating Metabolic Acidosis and Slowing the Progression of Chronic Kidney Disease Investor Presentation ? Year-End Business Update December 8, 2020 Exhibit 99. |
|
| December 8, 2020 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 8, 2020 TRICIDA, INC. (Exact name of Registrant as specified in its charter) Delaware 001-38558 46-3372526 (State or other jurisdiction of incorporation) (Commission File Num |
|
| December 8, 2020 |
Exhibit 99.2 FOR IMMEDIATE RELEASE Tricida Announces Updates on Veverimer Development Program, Regulatory Status and New Patent Extending Protection through 2038 SOUTH SAN FRANCISCO, Calif., December 8, 2020 ? Tricida, Inc. (Nasdaq: TCDA), a pharmaceutical company focused on the development and commercialization of its investigational drug candidate, veverimer (TRC101), a non-absorbed, orally-admi |
|
| December 4, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 4, 2020 TRICIDA, INC. (Exact name of Registrant as specified in its charter) Delaware 001-38558 46-3372526 (State or other jurisdiction of incorporation) (Commission File Num |
|
| November 9, 2020 |
Tricida Announces Third Quarter 2020 Financial Results Exhibit 99.1 FOR IMMEDIATE RELEASE Tricida Announces Third Quarter 2020 Financial Results SOUTH SAN FRANCISCO, Calif., November 9, 2020 — Tricida, Inc. (Nasdaq: TCDA), a pharmaceutical company focused on the development and commercialization of its investigational drug candidate, veverimer (TRC101), a non-absorbed, orally-administered polymer designed to treat metabolic acidosis in patients with c |
|
| November 9, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 9, 2020 TRICIDA, INC. (Exact name of Registrant as specified in its charter) Delaware 001-38558 46-3372526 (State or other jurisdiction of incorporation) (Commission File Num |
|
| November 9, 2020 |
tricidaincexecutivereten Exhibit 10.1 Retention Agreement Dear [Name], In recognition of the important role you have today and in anticipation of your contributions moving forward, Tricida, Inc. (“Company”) is offering you retention awards in the form of equity and cash. The equity and cash awards are granted pursuant to, and subject to the terms of, the Tricida, Inc. 2018 Equity Incentive Plan (t |
|
| November 9, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38558 TRICIDA, INC. (E |
|
| October 29, 2020 |
tricidatypeameetingcall Exhibit 99.1 Treating Metabolic Acidosis and Slowing the Progression of Chronic Kidney Disease Investor Presentation – End-of-Review Type A Meeting Update October 2020 Forward Looking Statements Any statements contained in this presentation or made during the accompanying oral presentation that are not statements of historical facts are forward-looking statements as defined |
|
| October 29, 2020 |
fdatypeameetingupdateex Exhibit 99.2 FOR IMMEDIATE RELEASE Tricida Provides Update on FDA Interactions SOUTH SAN FRANCISCO, Calif., October 29, 2020 — Tricida, Inc. (Nasdaq: TCDA), a pharmaceutical company focused on the development and commercialization of its investigational drug candidate, veverimer (TRC101), a non-absorbed, orally-administered polymer designed to treat metabolic acidosis in pa |
|
| October 29, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 25, 2020 TRICIDA, INC. (Exact name of Registrant as specified in its charter) Delaware 001-38558 46-3372526 (State or other jurisdiction of incorporation) (Commission File Num |
|
| August 24, 2020 |
Exhibit 99.1 FOR IMMEDIATE RELEASE Tricida Receives Complete Response Letter from the FDA for its New Drug Application for Veverimer for the Treatment of Metabolic Acidosis and Slowing of Kidney Disease Progression in Patients with Metabolic Acidosis Associated with CKD SOUTH SAN FRANCISCO, Calif., August 24, 2020 (Business Wire) — Tricida, Inc. (Nasdaq: TCDA), a pharmaceutical company focused on |
|
| August 24, 2020 |
Financial Statements and Exhibits, Other Events - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 21, 2020 TRICIDA, INC. (Exact name of Registrant as specified in its charter) Delaware 001-38558 46-3372526 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| August 6, 2020 |
tricida-2018esppfinalame EXHIBIT 10.4 TRICIDA, INC. EMPLOYEE STOCK PURCHASE PLAN 1. Purpose. The purpose of this Plan is to provide Employees of the Company and Participating Subsidiaries with an opportunity to purchase common stock of the Company through accumulated payroll deductions. It is the intention of the Company to have the Plan qualify as an “Employee Stock Purchase Plan” under Section 4 |
|
| August 6, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38558 TRICIDA, INC. (Exact |
|
| August 5, 2020 |
Tricida Announces Second Quarter 2020 Financial Results Webcast Today at 4:30 pm Eastern Time Exhibit 99.1 FOR IMMEDIATE RELEASE Tricida Announces Second Quarter 2020 Financial Results Webcast Today at 4:30 pm Eastern Time SOUTH SAN FRANCISCO, Calif., August 5, 2020 (Business Wire) — Tricida, Inc. (Nasdaq: TCDA), a pharmaceutical company focused on the development and commercialization of its drug candidate, veverimer (TRC101), a non-absorbed, orally-administered polymer designed to treat |
|
| August 5, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 5, 2020 TRICIDA, INC. (Exact name of Registrant as specified in its charter) Delaware 001-38558 46-3372526 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| July 15, 2020 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 14, 2020 TRICIDA, INC. (Exact name of Registrant as specified in its charter) Delaware 001-38558 46-3372526 (State or other jurisdiction of incorporation) (Commission File Number |
|
| July 15, 2020 |
Tricida Provides Regulatory Update on Veverimer EXHIBIT 99.1 FOR IMMEDIATE RELEASE Tricida Provides Regulatory Update on Veverimer SOUTH SAN FRANCISCO, Calif., July 15, 2020 (Business Wire) — Tricida, Inc. (Nasdaq: TCDA), a pharmaceutical company focused on the development and commercialization of its drug candidate, veverimer (TRC101), a non-absorbed, orally-administered polymer designed to treat metabolic acidosis in patients with chronic kid |
|
| June 30, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 29, 2020 TRICIDA, INC. (Exact name of Registrant as specified in its charter) Delaware 001-38558 46-3372526 (State or other jurisdiction of incorporation) (Commission File Number |
|
| June 16, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 11, 2020 TRICIDA, INC. (Exact name of Registrant as specified in its charter) Delaware 001-38558 46-3372526 (State or other jurisdiction of incorporation) (Commission File Number |
|
| June 16, 2020 |
certificateofincorporati EXHIBIT 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF TRICIDA, INC., a Delaware corporation Tricida, Inc., a corporation organized and existing under the laws of the State of Delaware (the “Corporation”), hereby certifies as follows: A. The name of the Corporation is Tricida, Inc. The Corporation was originally incorporated under the name Trilypsa, Inc. The Corp |
|
| June 3, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 x Filed by the Registrant ¨ Filed by a Party other than the Registrant Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Definitive Proxy Statement x Definitive Additional Materials ¨ Soliciting Material under § 240. |
|
| May 22, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 22, 2020 TRICIDA, INC. (Exact name of Registrant as specified in its charter) Delaware 001-38558 46-3372526 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| May 22, 2020 |
convertiblenotesindentur EXHIBIT 4.1 TRICIDA, INC. AND U.S. BANK NATIONAL ASSOCIATION, AS TRUSTEE INDENTURE DATED AS OF MAY 22, 2020 3.50% CONVERTIBLE SENIOR NOTES DUE 2027 TABLE OF CONTENTS Page ARTICLE 1 DEFINITIONS ....................................................................................................... 1 1.01 Definitions............................................................ |
|
| May 22, 2020 |
EXHIBIT 99.1 FOR IMMEDIATE RELEASE Tricida Announces Closing of Offering of $200 Million of 3.50% Convertible Senior Notes Due 2027, Including Full Exercise of Option to Purchase Additional Notes SOUTH SAN FRANCISCO, Calif., May 22, 2020 (Business Wire) – Tricida, Inc. (Nasdaq: TCDA), a pharmaceutical company focused on the development and commercialization of its drug candidate, veverimer (TRC101 |
|
| May 20, 2020 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 19, 2020 TRICIDA, INC. (Exact name of Registrant as specified in its charter) Delaware 001-38558 46-3372526 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| May 20, 2020 |
Tricida Prices Offering of $175 Million 3.50% Convertible Senior Notes Due 2027 Exhibit 99.2 FOR IMMEDIATE RELEASE Tricida Prices Offering of $175 Million 3.50% Convertible Senior Notes Due 2027 SOUTH SAN FRANCISCO, Calif., May 19, 2020 (Business Wire) – Tricida, Inc. (Nasdaq: TCDA), a pharmaceutical company focused on the development and commercialization of its drug candidate, veverimer (TRC101), a non-absorbed, orally-administered polymer designed to treat metabolic acidos |
|
| May 20, 2020 |
Tricida Announces Proposed Offering of $175 Million Convertible Senior Notes Due 2027 Exhibit 99.1 FOR IMMEDIATE RELEASE Tricida Announces Proposed Offering of $175 Million Convertible Senior Notes Due 2027 SOUTH SAN FRANCISCO, Calif., May 19, 2020 (Business Wire) – Tricida, Inc. (Nasdaq: TCDA) today announced that it intends to offer $175.0 million aggregate principal amount of its Convertible Senior Notes due 2027 (the “Notes”) in a private offering (the “offering”) to qualified |
|
| May 19, 2020 |
EXHIBIT 10.1 FIFTH AMENDMENT TO LOAN AND SECURITY AGREEMENT This FIFTH AMENDMENT TO LOAN AND SECURITY AGREEMENT (this “Amendment”), dated as of May 18, 2020 (the “Fifth Amendment Effective Date”), is entered into by and among Tricida, Inc. (the “Borrower”), the several banks and other financial institutions or entities from time to time party thereto (collectively, “Lender”), Hercules Capital, Inc |
|
| May 19, 2020 |
EXHIBIT 10.3 THIS WARRANT, AND THE SECURITIES ISSUABLE UPON THE EXERCISE OF THIS WARRANT, HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR ANY STATE SECURITIES LAWS. THEY MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED, OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT RELATED THERETO OR AN OPINION OF COUNSEL (WHICH MAY BE COMPANY COUNSEL) REASON |
|
| May 19, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 18, 2020 TRICIDA, INC. (Exact name of Registrant as specified in its charter) Delaware 001-38558 46-3372526 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| May 19, 2020 |
EXHIBIT 10.2 THIS WARRANT, AND THE SECURITIES ISSUABLE UPON THE EXERCISE OF THIS WARRANT, HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR ANY STATE SECURITIES LAWS. THEY MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED, OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT RELATED THERETO OR AN OPINION OF COUNSEL (WHICH MAY BE COMPANY COUNSEL) REASON |
|
| May 8, 2020 |
EXHIBIT 10.2 FOURTH AMENDMENT TO LOAN AND SECURITY AGREEMENT This FOURTH AMENDMENT TO LOAN AND SECURITY AGREEMENT (this “Amendment”), dated as of March 31, 2020 (the “Amendment Effective Date”), is entered into by and among Tricida, Inc. (the “Borrower”), the several banks and other financial institutions or entities from time to time party thereto (collectively, “Lender”), Hercules Capital, Inc. |
|
| May 8, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38558 TRICIDA, INC. (Exact |
|
| May 7, 2020 |
Tricida Announces First Quarter 2020 Financial Results Webcast Today at 4:30 pm Eastern Time Exhibit 99.1 FOR IMMEDIATE RELEASE Tricida Announces First Quarter 2020 Financial Results Webcast Today at 4:30 pm Eastern Time SOUTH SAN FRANCISCO, Calif., May 7, 2020 (Business Wire) — Tricida, Inc. (Nasdaq: TCDA), a pharmaceutical company focused on the development and commercialization of its drug candidate, veverimer (TRC101), a non-absorbed, orally-administered polymer designed to treat meta |
|
| May 7, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 7, 2020 TRICIDA, INC. (Exact name of Registrant as specified in its charter) Delaware 001-38558 46-3372526 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| April 29, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy Statement ☒ Definitive Additional Materials ☐ Soliciting Material under § 240. |
|
| April 29, 2020 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy Statement ☐ Definitive Additional Materials ☐ Soliciting Material under § 240. |
|
| April 17, 2020 |
TCDA / Tricida, Inc. PRE 14A - - PRE 14A TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy Statement ☐ Definitive Additional Materials ☐ Soliciting Material under § 240. |
|
| April 15, 2020 |
tricidacorporatepresenta Treating Metabolic Acidosis and Slowing the Progression of Chronic Kidney Disease Investor Presentation April 2020 Forward Looking Statements Any statements contained in this presentation or made during the accompanying oral presentation that are not statements of historical facts are forward-looking statements as defined under the Federal securities laws. |
|
| April 15, 2020 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 14, 2020 TRICIDA, INC. (Exact name of Registrant as specified in its charter) Delaware 001-38558 46-3372526 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| March 16, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 10, 2020 TRICIDA, INC. (Exact name of Registrant as specified in its charter) Delaware 001-38558 46-3372526 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| March 2, 2020 |
As filed with the Securities and Exchange Commission on March 2, 2020 Registration No. |
|
| March 2, 2020 |
Description of the Company's Common Stock, $0.001 par value Exhibit 4.10 DESCRIPTION OF REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The authorized capital stock of Tricida, Inc. consists of 440,000,000 shares, consisting of 400,000,000 shares of common stock, pas value $0.001 per share (the “common stock”) and 40,000,000 shares of preferred stock, par value $0.001 per share (the “preferred stock”). We ha |
|
| March 2, 2020 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period From To Commission File Number: 001-38558 TRICIDA, INC. (Exact name of |
|
| March 2, 2020 |
Exhibit 4.9 THIS WARRANT, AND THE SECURITIES ISSUABLE UPON THE EXERCISE OF THIS WARRANT, HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR ANY STATE SECURITIES LAWS. THEY MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED, OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT RELATED THERETO OR AN OPINION OF COUNSEL (WHICH MAY BE COMPANY COUNSEL) REASONA |
|
| March 2, 2020 |
Exhibit 10.15 * CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. MANUFACTURING AND COMMERCIAL SUPPLY AGREEMENT (Veverimer) THIS MANUFACTURING AND COMMERCIAL SUPPLY AGREEMENT (“CSA” or “Agreement”) is made effective as of the last date of signat |
|
| February 28, 2020 |
Exhibit 10.1 TRICIDA, INC. EXECUTIVE SEVERANCE BENEFIT PLAN (as amended and restated on February 24, 2020) Section 1.Introduction The Tricida, Inc. Executive Severance Benefit Plan (the "Plan") was established effective March 31, 2014, amended and restated on July 2, 2018 and amended and restated on February 24, 2020. The purpose of the Plan is to provide for the payment of severance benefits to c |
|
| February 28, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 24, 2020 TRICIDA, INC. (Exact name of Registrant as specified in its charter) Delaware 001-38558 46-3372526 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| February 27, 2020 |
Exhibit 99.1 FOR IMMEDIATE RELEASE Tricida Announces Fourth Quarter and Full-Year 2019 Financial Results Webcast Today at 4:30 pm Eastern Time SOUTH SAN FRANCISCO, Calif., February 27, 2020 (Business Wire) — Tricida, Inc. (Nasdaq: TCDA), a pharmaceutical company focused on the development and commercialization of its drug candidate, veverimer (TRC101), a non-absorbed, orally-administered polymer d |
|
| February 27, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 27, 2020 TRICIDA, INC. (Exact name of Registrant as specified in its charter) Delaware 001-38558 46-3372526 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| January 27, 2020 |
TCDA / Tricida, Inc. / Wellington Management Group LLP - SEC SCHEDULE 13G Passive Investment SC 13G/A 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* TRICIDA, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 89610F101 (CUSIP Number) December 31, 2019 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to desig |
|
| January 13, 2020 |
tricidacorporatepresenta Treating Metabolic Acidosis and Slowing the Progression of Chronic Kidney Disease January 2020 Forward Looking Statements Any statements contained in this presentation or made during the accompanying oral presentation that are not statements of historical facts are forward-looking statements as defined under the Federal securities laws. |
|
| January 13, 2020 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 13, 2020 TRICIDA, INC. (Exact name of Registrant as specified in its charter) Delaware 001-38558 46-3372526 (State or other jurisdiction of incorporation) (Commission File Num |
|
| December 18, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 13, 2019 TRICIDA, INC. (Exact name of Registrant as specified in its charter) Delaware 001-38558 46-3372526 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| December 12, 2019 |
EXHIBIT 1 JOINT FILING AGREEMENT The undersigned hereby agree that the Statement on this Schedule 13D, dated December 12, 2019 (the “Schedule 13D”), with respect to the Shares of Tricida, Inc. |
|
| December 12, 2019 |
TCDA / Tricida, Inc. / ORBIMED ADVISORS LLC - AMENDMENT NO. 2 Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2) TRICIDA, INC. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 89610F101 (CUSIP Number) OrbiMed Advisors LLC OrbiMed Capital GP V LLC 601 Lexington Avenue, 54th Floor New York, NY 10022 Telephone: (212) 739-6400 (Name, Address and Telephone Nu |
|
| November 27, 2019 |
TCDA / Tricida, Inc. / Sibling Capital Ventures Llc - SC 13D/A Activist Investment SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2) Tricida, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 89610F101 (CUSIP Number) Sibling Capital Ventures LLC c/o Brian Isern 500 Yale Avenue North Seattle, WA 98109 Tel: (504) 715-8335 (Name, Addres |
|
| November 14, 2019 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2019 TRICIDA, INC. (Exact name of Registrant as specified in its charter) Delaware 001-38558 46-3372526 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| November 14, 2019 |
Exhibit 99.1 FOR IMMEDIATE RELEASE Tricida Announces Third Quarter 2019 Financial Results FDA Accepts New Drug Application for Veverimer Webcast Today at 4:30 pm Eastern Time SOUTH SAN FRANCISCO, Calif., November 14, 2019 (Business Wire) — Tricida, Inc. (Nasdaq: TCDA), a pharmaceutical company focused on the development and commercialization of its drug candidate, veverimer (TRC101), a non-absorbe |
|
| November 14, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38558 TRICIDA, INC. (E |
|
| October 15, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 15, 2019 TRICIDA, INC. (Exact name of Registrant as specified in its charter) Delaware 001-38558 46-3372526 (State or other jurisdiction of incorporation) (Commission File Num |
|
| October 10, 2019 |
Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 4, 2019 TRICIDA, INC. (Exact name of Registrant as specified in its charter) Delaware 001-38558 46-3372526 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| September 4, 2019 |
Tricida Announces Submission of New Drug Application for Veverimer for the Treatment of Metabolic Acidosis in Patients with Chronic Kidney Disease NDA Submitted under the FDA’s Accelerated Approval Program SOUTH SAN FRANCISCO, Calif. |
|
| September 4, 2019 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 4, 2019 TRICIDA, INC. (Exact name of Registrant as specified in its charter) Delaware 001-38558 46-3372526 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| August 19, 2019 |
Exhibit 10.1 THIRD AMENDMENT TO LEASE THIS THIRD AMENDMENT TO LEASE (this “Third Amendment”) is made as of August 14, 2019, by and between ARE-SAN FRANCISCO NO. 17, LLC, a Delaware limited liability company (“Landlord”), and TRICIDA, INC., a Delaware corporation (“Tenant”). RECITALS A. Landlord and Tenant are now parties to that certain Lease Agreement dated as of April 4, 2014, as amended by that |
|
| August 19, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 14, 2019 TRICIDA, INC. (Exact name of Registrant as specified in its charter) Delaware 001-38558 46-3372526 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| August 19, 2019 |
Exhibit 99.1 SECOND AMENDMENT TO LEASE THIS SECOND AMENDMENT TO LEASE (this " Second Amendment" ) is made as of November 7, 2017, by and between ARE-SAN FRANCISCO NO. 17, LLC, a Delaware limited liability company ("Landlord"), and TRICIDA, INC., a Delaware corporation ("Tenant"). RECITALS A.Landlord and Tenant are now parties to that certain Lease Agreement dated as of April 4, 2014, as amended by |
|
| August 9, 2019 |
Exhibit 4.11 TRICIDA, INC. Reconciliation and tie between the Trust Indenture Act of 1939 and the Indenture Trust Indenture Act Section Indenture Section Sec. 310(a)(1) 607 (a)(2) 607 (b) 608 Sec. 312(c) 701 Sec. 314(a) 703 (c)(1) 102 (c)(2) 102 (e) 102 Sec. 315(b) 601 Sec. 316(a) (last sentence) 101 (“Outstanding”) (a)(1)(A) Article 5 (a)(1)(B) Article 5 (b) Article 5 (c) 104(c) Sec. 317(a)(1) Ar |
|
| August 9, 2019 |
TCDA / Tricida, Inc. S-3ASR - - S-3ASR As filed with the Securities and Exchange Commission on August 9, 2019 Registration No. |
|
| August 9, 2019 |
As filed with the Securities and Exchange Commission on August 9, 2019 Registration No. |
|
| August 9, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38558 TRICIDA, INC. (Exact |
|
| August 8, 2019 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2019 TRICIDA, INC. (Exact name of Registrant as specified in its charter) Delaware 001-38558 46-3372526 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| August 8, 2019 |
Exhibit 99.1 Tricida Announces Second Quarter 2019 Financial Results Narrows Timing of Planned NDA Submission to the Third Quarter of 2019 Back-to-Back Publications in ‘The Lancet’ Highlight Positive Clinical Trial Results of Veverimer Webcast Today at 4:30 pm Eastern Time SOUTH SAN FRANCISCO, Calif., August 8, 2019 (Business Wire) — Tricida, Inc. (Nasdaq: TCDA), a pharmaceutical company focused o |
|
| June 25, 2019 |
Exhibit 99.1 FOR IMMEDIATE RELEASE Tricida Announces Publication of Positive Long-Term Phase 3 Clinical Trial Results of Veverimer (TRC101) in The Lancet TRCA-301E trial is the first, long-term, randomized, multicenter, blinded, placebo-controlled trial to evaluate the treatment of metabolic acidosis in patients with CKD SOUTH SAN FRANCISCO, Calif., June 25, 2019 (Business Wire) - Tricida, Inc. (N |
|
| June 25, 2019 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 25, 2019 TRICIDA, INC. (Exact name of Registrant as specified in its charter) Delaware 001-38558 46-3372526 (State or other jurisdiction of incorporation) (Commission File Number |
|
| May 31, 2019 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 31, 2019 TRICIDA, INC. (Exact name of registrant as specified in its charter) Delaware 001-38558 46-3372526 (State or other jurisdiction (Commission (IRS Employer of incorporation |
|
| May 10, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ý QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2019 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38558 TRICIDA, INC. (Exact |
|
| May 8, 2019 |
Tricida Announces First Quarter 2019 Financial Results Webcast Today at 4:30 pm Eastern Time Exhibit 99.1 Tricida Announces First Quarter 2019 Financial Results Webcast Today at 4:30 pm Eastern Time SOUTH SAN FRANCISCO, Calif., May 8, 2019 (Business Wire) — Tricida, Inc. (Nasdaq: TCDA), a pharmaceutical company focused on the development and commercialization of its drug candidate, veverimer (TRC101), a non-absorbed, orally-administered polymer designed to treat metabolic acidosis in pati |
|
| May 8, 2019 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2019 TRICIDA, INC. (Exact name of Registrant as specified in its charter) Delaware 001-38558 46-3372526 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| April 18, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) Information Required in Proxy Statement Schedule 14A Information Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confide |
|
| April 18, 2019 |
TCDA / Tricida, Inc. DEFINITIVE PROXY STATEMENT TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy Statement ☐ Definitive Additional Materials ☐ Soliciting Material under § 240. |
|
| April 11, 2019 |
TCDA / Tricida, Inc. / Sibling Capital Ventures Llc - SC 13D/A Activist Investment SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1) Tricida, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 89610F101 (CUSIP Number) Sibling Capital Ventures LLC c/o Brian Isern 500 Yale Avenue North Seattle, WA 98109 Tel: (504) 715-8335 (Name, Addres |
|
| April 11, 2019 |
EX-99.B EXHIBIT B Tricida, Inc. Lock-Up Agreement , 2019 Goldman Sachs & Co. LLC J.P. Morgan Securities LLC Cowen and Company, LLC As representatives of the several Underwriters named in Schedule I to the Underwriting Agreement, c/o Goldman Sachs & Co. LLC 200 West Street New York, New York 10282 c/o J.P. Morgan Securities LLC 383 Madison Avenue New York, New York 10179 c/o Cowen and Company, LLC |
|
| April 11, 2019 |
EX-99.D EXHIBIT D TRICIDA, INC. WAIVER OF REGISTRATION RIGHTS This Waiver of Registration Rights (this “Waiver”) is entered into as of March 25, 2019, by and among Tricida, Inc., a Delaware corporation (the “Company”), and certain of its stockholders set forth on the signature pages hereto. Capitalized terms used in this Waiver and not otherwise defined herein shall have the meanings given them in |
|
| April 9, 2019 |
EXHIBIT 1 JOINT FILING AGREEMENT The undersigned hereby agree that the Statement on this Schedule 13D, dated July 11, 2018 (the “Schedule 13D”), with respect to the Shares of Tricida, Inc. |
|
| April 9, 2019 |
TCDA / Tricida, Inc. / ORBIMED ADVISORS LLC - AMENDMENT NO. 1 Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1) TRICIDA, INC. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 89610F101 (CUSIP Number) OrbiMed Advisors LLC OrbiMed Capital GP V LLC 601 Lexington Avenue, 54th Floor New York, NY 10022 Telephone: (212) 739-6400 (Name, Address and Telephone Nu |
|
| April 5, 2019 |
Filed Pursuant to Rule 424(b)(4) Registration Numbers 333-230657 and 333-230713 5,600,000 Shares Common Stock We are offering 5,600,000 shares of common stock. |
|
| April 3, 2019 |
As filed with the Securities and Exchange Commission on April 3, 2019 Registration Number 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| April 1, 2019 |
As filed with the Securities and Exchange Commission on April 1, 2019. Registration Number 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 TRICIDA, INC. (Exact name of registrant as specified in its charter) Delaware 2834 46-3372526 (State or other jurisdiction of incorporation or organization) (Primary S |
|
| April 1, 2019 |
Form of Underwriting Agreement, including form of lock-up agreement. Exhibit 1.1 Tricida, Inc. Common Stock, par value $0.001 per share Underwriting Agreement [•], 2019 Goldman Sachs & Co. LLC J.P. Morgan Securities LLC Cowen and Company, LLC As representatives (the “Representatives”) of the several Underwriters named in Schedule I hereto c/o Goldman Sachs & Co. LLC 200 West Street New York, New York 10282 c/o J.P. Morgan Securities LLC 383 Madison Avenue New York, |
|
| April 1, 2019 |
TCDA / Tricida, Inc. 10-K/A (Annual Report) SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K/A (Amendment No. 1) (Mark One) ý ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2018 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38558 TRICIDA, |
|
| April 1, 2019 |
April 1, 2019 Via EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549-3720 Attention: Jeffrey Gabor Re: Acceleration Request for Tricida, Inc. Registration Statement on Form S-1 (File No. 333-230657) Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended, Tricida, Inc. (the “Company”), hereby reque |
|
| April 1, 2019 |
April 1, 2019 United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| March 29, 2019 |
TCDA / Tricida, Inc. 10-K (Annual Report) SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ý ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2018 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period From To Commission File Number: 001-38558 TRICIDA, INC. (Exact name of |
|
| March 28, 2019 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 28, 2019 TRICIDA, INC. (Exact name of Registrant as specified in its charter) Delaware 001-38558 46-3372526 (State or other jurisdiction of incorporation) (Commission File Numbe |
